GPC chronicles

Although the exercises of stock options and convertible bonds by GPC executives over the past year were part of a pre-arranged trading plan, the timing of the transactions left some investors unhappy, as management cashed in prior to the negative FDA panel on lead compound Orplatna satraplatin for hormone-refractory prostate cancer (HRPC). Below are selected events tracked against GPC's daily stock price. Periods of option and convertible bond exercises shaded below. Source: Stock option/convertible bond transactions from GPC's website A. 12/11/06 to 1/19/07 - Four GPC executives - CEO Bernd Seizinger, SVP of Business Development Elmar Maier, CFO Mirko Scherer and CSO Sebastian Meier-Ewert - receive proceeds of at least E6.5M ($8.5M) through the exercise and sale of stock options and convertible bonds B. 1/24/07 - GPC raises E33.6M ($43.6M) in a private placementC. 2/16/07 - Completes submission of a rolling NDA to FDA for Orplatna plus prednisone to treat HRPCD. 5/21/07 to 7/19/07 - Seizinger, Maier, Scherer and Meier-Ewert receive proceeds of at least E3.7M ($5M) through the exercise and sale of stock options and convertible bonds

E. 6/25/07 - Grants Yakult Honsha exclusive rights to develop and commercialize Orplatna in Japan...